Obesity Clinical Trial Tracker — GLP-1, GIPR, Amylin, and Novel Weight Loss Trials 2026

Why obesity trial monitoring matters

Obesity — defined as BMI ≥30 kg/m², or BMI ≥27 with at least one weight-related comorbidity — affects over 650 million adults globally and is a primary driver of type 2 diabetes, cardiovascular disease, nonalcoholic steatohepatitis (MASH), obstructive sleep apnea, and several malignancies. The clinical development landscape has been transformed by incretin-based therapies: semaglutide (Ozempic/Wegovy, Novo Nordisk) and tirzepatide (Mounjaro/Zepbound, Eli Lilly) have demonstrated 15–22% mean body weight reductions in pivotal trials — figures that rival bariatric surgery in some populations — and have driven an unprecedented wave of investment and clinical activity in the metabolic disease space.

With approximately 150 recruiting obesity trials currently registered on ClinicalTrials.gov, this is one of the most competitive development arenas in all of medicine. Key signals to track include:

• Next-generation GLP-1/GIPR/GCG triple agonists (retatrutide, mazdutide) advancing into Phase 3
• Oral GLP-1 receptor agonists (orforglipron, danuglipron) seeking to replicate injectable efficacy in pill form
• Amylin analog combinations — cagrilintide plus semaglutide (CagriSema) targeting 25%+ weight loss
• Non-hormonal mechanisms: glucagon receptor agonism, CNS-targeting agents, and PCSK9 pathway combinations
• Cardiometabolic outcomes trials expanding from MACE to heart failure, kidney disease, MASH, and sleep apnea endpoints
• Combination pharmacotherapy strategies pairing incretin agents with amylin, NPY, or oxyntomodulin analogs
• Pediatric and adolescent obesity programs following adult regulatory approvals

What we monitor for obesity

Our pipeline pulls directly from the ClinicalTrials.gov API every day. For an obesity watch profile, you can configure:

• Condition keywords: "obesity", "overweight", "weight management", "BMI 30", "adiposity", "metabolic syndrome", "weight loss", "anti-obesity"
• Intervention keywords: "semaglutide", "tirzepatide", "retatrutide", "orforglipron", "danuglipron", "cagrilintide", "GLP-1", "GIPR", "amylin", "GLP-1 receptor agonist", "incretin"
• Phase filter: Phase 1 only, Phase 2/3, or all phases
• Sponsor filter: Industry-sponsored only (for competitive intelligence) or all sponsors
• Status filter: Recruiting only, all active studies, or any status

The obesity treatment landscape in 2026

GLP-1 receptor agonists: semaglutide and the SELECT generation

Semaglutide 2.4 mg weekly subcutaneous (Wegovy) achieved FDA approval for chronic weight management in 2021 following the STEP 1–4 trials (NCT03548935 and related), which demonstrated 14.9–17.4% mean weight reduction from baseline. The SELECT cardiovascular outcomes trial (NCT03574597) subsequently demonstrated a 20% reduction in major adverse cardiovascular events (MACE) in overweight and obese adults with established cardiovascular disease but without diabetes — establishing semaglutide as a cardioprotective agent beyond glycemic control and driving label expansion. Oral semaglutide is being evaluated at higher doses (25 mg, 50 mg) in obesity-specific Phase 3 programs. The approved GLP-1 agonist class also includes liraglutide (Saxenda), which predates semaglutide but has been largely supplanted by superior efficacy agents. Development activity has shifted decisively toward higher-efficacy combination mechanisms.

GIPR dual agonists: tirzepatide and the SURMOUNT program

Tirzepatide (Zepbound, Eli Lilly) — a dual GIP/GLP-1 receptor agonist — achieved FDA approval for obesity in November 2023 following the SURMOUNT-1 trial (NCT04184622), which demonstrated up to 22.5% mean weight loss at the highest dose — the largest weight reduction ever reported for a pharmacological agent in a pivotal trial. SURMOUNT-2 (NCT04657003) established efficacy in type 2 diabetes with obesity, and SURMOUNT-4 (NCT05463679) assessed weight regain prevention after treatment withdrawal. The SURMOUNT-MMO cardiovascular outcomes trial is evaluating MACE reduction in obese adults without diabetes. Tirzepatide's success has confirmed that GIP receptor co-agonism additively enhances GLP-1-mediated weight loss and has set a new efficacy benchmark against which all successor agents are measured. Monitoring SURMOUNT-program amendments and new Lilly obesity registrations provides early signals on Phase 3 completions and label expansion strategies.

GLP-1/GIPR/GCG triple agonists: retatrutide and beyond

Retatrutide (LY3437943, Eli Lilly) — a GLP-1/GIPR/glucagon receptor triple agonist — produced remarkable Phase 2 results (NCT04881357) demonstrating up to 24.2% weight reduction at 48 weeks, approaching the efficacy range of bariatric surgery in the subset of high-dose completers. Glucagon receptor co-agonism augments energy expenditure and hepatic fat mobilization, potentially delivering metabolic benefits beyond weight reduction alone — including MASH resolution, dyslipidemia improvement, and enhanced thermogenesis. Retatrutide has entered Phase 3 development. Competing triple agonist programs include mazdutide (IBI362, Innovent/Eli Lilly), pemvidutide (Altimmune), and CT-388 (Carmot Therapeutics/Roche), each with differentiated receptor selectivity profiles and pharmacokinetic designs. Monitoring these Phase 1/2 registrations provides 18–30 months of lead time before pivotal data disclosure.

Oral GLP-1 agents: orforglipron and danuglipron

Oral bioavailability has been the longstanding limitation of GLP-1 receptor agonist therapy — semaglutide oral (Rybelsus) requires fasting administration and achieves limited oral bioavailability, constraining dose range. Non-peptide small-molecule GLP-1 receptor agonists overcome this constraint: orforglipron (LY3502970, Eli Lilly) and danuglipron (PF-06882961, Pfizer) demonstrated meaningful weight loss in Phase 2 trials and have entered or are approaching Phase 3 evaluation. Orforglipron Phase 2 data (NCT04022187) showed 9–14% weight reduction without food-timing restrictions. Phase 3 oral programs represent a potential step-change in market access — patients who cannot tolerate injections or are injection-naive represent a substantially larger addressable population than current injectables reach. Competitive intelligence on oral GLP-1 Phase 3 design, endpoints, and enrollment milestones is high-value for pharma portfolio teams and investors tracking next-generation platform differentiation.

Amylin analogs and combination approaches: cagrilintide and CagriSema

Amylin is a pancreatic peptide co-secreted with insulin that reduces food intake and slows gastric emptying via central nervous system receptors distinct from the GLP-1 pathway. Cagrilintide (Novo Nordisk) is a long-acting amylin analog designed for once-weekly subcutaneous administration. In Phase 2, cagrilintide monotherapy produced dose-dependent weight loss. The transformative opportunity lies in combination: CagriSema (cagrilintide 2.4 mg plus semaglutide 2.4 mg, Novo Nordisk) has entered Phase 3 (REDEFINE program, NCT05567354) after Phase 2 results demonstrating approximately 15.6% weight reduction at 32 weeks — with the hypothesis that the full 52-week results will reach or exceed 25%. If this benchmark is achieved, CagriSema would represent a non-surgical path to weight loss previously accessible only through bariatric procedures, with implications for obesity-related comorbidity reversal. Monitoring REDEFINE enrollment milestones and protocol amendments is essential for competitive tracking of the Novo Nordisk obesity pipeline.

Non-hormonal mechanisms and CNS-targeting agents

The GLP-1 wave has attracted attention to mechanistically distinct obesity targets. Bimagrumab (Novartis/Versanis) — an anti-ActRII antibody targeting muscle mass preservation during weight loss — entered Phase 2 trials evaluating body composition outcomes alongside fat mass reduction. Setmelanotide (Imcivree, Rhythm Pharmaceuticals) is approved for rare monogenic obesity conditions (MC4R pathway deficiencies) and is being evaluated in broader polygenic obesity populations. NPY/AgRP pathway antagonists, GIP receptor-selective agonists in isolation, and oxyntomodulin analogs are progressing through early Phase 1 programs. Central nervous system targeting — exploiting hypothalamic circuits that regulate energy homeostasis — represents a mechanistic frontier with multiple pre-clinical programs approaching first-in-human studies. Tracking early-phase registrations provides insight into mechanisms likely to generate Phase 2 data in 2027–2029.

Cardiometabolic outcomes trials: beyond MACE

The SELECT trial established that obesity pharmacotherapy can reduce cardiovascular events independent of glycemic effects — a paradigm shift that has broadened the indication and payer rationale for GLP-1-based agents. The development pipeline has expanded to encompass outcomes beyond MACE: FLOW (NCT03819153) demonstrated semaglutide-mediated kidney protection in chronic kidney disease with type 2 diabetes; STEP-HFpEF (NCT04788511) established benefit in heart failure with preserved ejection fraction; and multiple MASH trials are evaluating GLP-1 and triple agonist agents for histological resolution of nonalcoholic steatohepatitis — an indication with large unmet need and a favorable regulatory environment. Monitoring outcomes trial registrations and protocol amendments provides early signals on emerging label expansions before pivotal data readouts.

Who uses obesity trial monitoring

Endocrinologists and obesity medicine specialists

Endocrinologists at academic medical centers and obesity medicine specialists in clinical practice track new trial registrations to identify patient referral opportunities, monitor evolving combination therapy evidence, and stay current on mechanism-of-action differentiation before conference presentations. With approximately 150 recruiting trials active at any given time, systematic monitoring provides structured intelligence that manual ClinicalTrials.gov searches cannot efficiently deliver. Drug mechanism awareness — understanding where orforglipron or CagriSema sit in the pipeline — directly informs prescribing rationale and patient expectation-setting for patients inquiring about next-generation agents.

Pharma and biotech BD and competitive intelligence teams

Business development teams at Novo Nordisk, Eli Lilly, Pfizer, AstraZeneca, Boehringer Ingelheim, Roche, and emerging metabolic disease biotechs track competitor trial registrations to monitor mechanism differentiation, enrollment timelines, and endpoint strategies. A new Phase 1 registration for an oral GLP-1 agonist or an amylin combination may precede clinical data disclosure by 24–36 months. Given the density of the pipeline — with overlapping mechanisms, similar endpoints, and compressed development timelines — systematic monitoring of new registrations is the most reliable competitive intelligence input available between IQVIA reports and conference abstracts.

Metabolic disease investors and portfolio managers

Investors with exposure to GLP-1 platform companies, metabolic disease biotechs, and device companies affected by pharmacotherapy adoption — bariatric surgery device makers, continuous glucose monitoring manufacturers, cardiovascular device companies — track obesity trial activity as a leading indicator of pipeline advancement and competitive landscape evolution. Phase 3 enrollment completion signals potential data catalysts 12–18 months ahead. New Phase 1 registrations by major pharma in oral formulations or novel mechanisms signal strategic conviction in adjacent program areas. Protocol amendments revealing endpoint changes or dose escalation decisions can be significant intelligence signals before any investor communications are issued.

Frequently asked questions

Can I track GLP-1 and oral agent programs separately from outcomes trials?

Yes. On the Pro plan ($99/month), you can create multiple search profiles. You might configure one profile for mechanism-of-action trials (keywords: "semaglutide", "tirzepatide", "orforglipron", "cagrilintide", "GLP-1 receptor agonist"), a second for cardiometabolic outcomes programs (keywords: "MACE", "heart failure", "kidney disease", "MASH", "cardiovascular outcomes"), and a third for early-phase novel mechanisms — each delivering a focused daily digest matched to your specific intelligence priorities.

Does this cover pediatric obesity and adolescent weight management trials?

Yes. You can configure condition keywords to capture pediatric-specific registrations: "pediatric obesity", "adolescent obesity", "childhood obesity", "weight management adolescent". Following adult approvals for semaglutide and tirzepatide, regulatory agencies and sponsors have initiated pediatric extension studies, and several dedicated adolescent obesity trials are now recruiting. These registrations appear in the same ClinicalTrials.gov feed and are captured by appropriately configured keyword profiles.

How is this different from manually searching ClinicalTrials.gov for obesity trials?

ClinicalTrials.gov requires manual daily searches with no structured alerting for new registrations, phase transitions, or enrollment status updates. With approximately 150 active obesity trials and rapid new registrations driven by the GLP-1 investment cycle, manual monitoring is impractical for comprehensive coverage. DataLookout delivers a filtered, labeled digest to your inbox each morning — covering new trial registrations, status changes from "not yet recruiting" to "recruiting", dose escalation amendments, and sponsor changes — so you spend time on analysis rather than search.